Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Treatment strategies in patients with core-binding factor acute myeloid leukemia.

Solis EC.

Curr Oncol Rep. 2011 Oct;13(5):359-60. doi: 10.1007/s11912-011-0183-y.

PMID:
21755276
2.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H.

Am J Hematol. 2014 Oct;89(10):964-8. doi: 10.1002/ajh.23795. Epub 2014 Jul 21.

3.

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.

Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.

Cancer. 2008 Dec 1;113(11):3181-5. doi: 10.1002/cncr.23927.

4.

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.

Am J Hematol. 2009 Nov;84(11):733-7. doi: 10.1002/ajh.21545.

5.

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.

Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.

Leuk Res. 2008 Dec;32(12):1800-8. doi: 10.1016/j.leukres.2008.05.011. Epub 2008 Jul 14.

PMID:
18621416
6.

Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.

Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O, Armendariz H, Dworzak M, Ha SY, Hasle H, Hovi L, Maschan A, Bertrand Y, Leverger GG, Razzouk BI, Rizzari C, Smisek P, Smith O, Stark B, Creutzig U.

J Clin Oncol. 2013 Feb 10;31(5):599-607. doi: 10.1200/JCO.2012.43.7384. Epub 2013 Jan 14.

PMID:
23319696
7.

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.

Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P.

Am J Hematol. 2014 Apr;89(4):399-403. doi: 10.1002/ajh.23653. Epub 2014 Mar 7.

8.

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW.

Blood. 2003 Dec 15;102(13):4277-83. Epub 2003 Aug 21.

9.

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D.

J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.

PMID:
23940227
10.

Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.

Parikh SA, Kadia T, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):301-2. doi: 10.3816/CLML.2010.n.062.

PMID:
20709669
11.

[Current and new therapeutic strategies in acute myeloid leukemia].

Naito K, Ohnishi K.

Gan To Kagaku Ryoho. 2005 Mar;32(3):292-6. Review. Japanese.

PMID:
15791811
12.

[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].

Hirayama Y, Terui T, Koike K, Neda H, Ishitani K, Kohda K, Kuroda H, Iyama S, Sato T, Kobune M, Takimoto R, Kato J.

Rinsho Ketsueki. 2009 Aug;50(8):663-5. Japanese.

PMID:
19915382
13.

Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.

Pirrotta MT, Bocchia M, Bucalossi A, Defina M, Forconi F, Gozzetti A, Lauria F.

Acta Haematol. 2007;118(1):7-9. Epub 2007 Mar 26. No abstract available.

PMID:
17389781
14.
15.

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.

Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.

Turk J Pediatr. 2000 Jul-Sep;42(3):198-204.

PMID:
11105617
16.

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):244-51. doi: 10.1016/j.clml.2012.03.003. Epub 2012 Apr 24.

17.

Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.

Tavil B, Aytac S, Balci YI, Unal S, Kuskonmaz B, Yetgin S, Gurgey A, Tuncer M, Gumruk F, Uckan D, Cetin M.

Pediatr Hematol Oncol. 2010 Oct;27(7):517-28. doi: 10.3109/08880018.2010.493578.

PMID:
20677923
18.

FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.

Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.

Ann Hematol. 2003 Apr;82(4):231-5. Epub 2003 Mar 15.

PMID:
12707726
20.

Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.

Malfuson JV, Konopacki J, Thepenier C, Eddou H, Foissaud V, de Revel T.

Ann Hematol. 2012 Dec;91(12):1871-7. doi: 10.1007/s00277-012-1528-9. Epub 2012 Jul 21.

PMID:
22820971

Supplemental Content

Support Center